AR and prostate cancer: On the GEO, there are 29 returns for “prostate cancer” with “AR-V7” and “Expression profiling with RNA-seq”, and whilst the majority of these assess novel inhibitors, 2 contain a small number CRPC patient-derived samples and 10 directly assess the impact of AR-V7 inhibition in PCa cell lines with siRNA, antibody, or shRNA (Table 2).